Treatment of acute myeloid leukemia patients aged more than 75 years: Results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG)

References

• Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985; 69: 5–11
   PubMedGoogle Scholar
• Groupe Francais de Morphologie Hematologique. French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982 – 1983 and classified according to FAB criteria. Cancer 1987; 60: 1385–1394
   PubMed Web of Science ®Google Scholar
• Johnson P RE, Liu Yin J A. Acute myeloid leukaemia in the elderly: biology and treatment. Br J Haematol 1993; 83: 1–6
   PubMed Web of Science ®Google Scholar
• Taylor P RA, Reid M M, Stark A N, Bown N, Hamilton P J, Proctor S J. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Leukemia 1995; 9: 231–237
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Smith S M, Le Beau M M, Huo D, Karrison T, Sobecks R M, Anastasi J, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003; 102: 43–52
   PubMed Web of Science ®Google Scholar
• Leone G, Voso M T, Sica S, Morosetti R, Pagano L. Therapy related leukemias: susceptibility, prevention and treatment. Leuk Lymphoma 2001; 41: 255–276
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Baudard M, Marie J P, Cadiou M, Viguié F, Zittoun R. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994; 86: 82–91
   PubMed Web of Science ®Google Scholar
• Stone R M, Mayer R J. The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 1993; 7: 65–79
   PubMed Web of Science ®Google Scholar
• DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996; 93: 89–95
   PubMed Web of Science ®Google Scholar
• Ferrara F, Annunziata M, Copia C, Magrin S, Mele G, Mirto S. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83: 126–131
   PubMed Web of Science ®Google Scholar
• Vey N, Coso D, Bardou V J, Stoppa A M, Braud A C, Bouabdallah R, et al. The benefit of induction chemotherapy in patients age ≥ 75 years. Cancer 2004; 101: 325–331
   PubMed Web of Science ®Google Scholar
• Mori M, Nisimura H, Urabe A, Tamura K, Makino S, Okabe K, et al. A randomized trial of conventional dose versus reduced dose in BHAC-DM therapy for acute myelogenous leukemia in elderly patients. Jpn J Clin Hematol 2000; 41: 109–114
   PubMedGoogle Scholar
• Kimura K, Ohno R, Amaki I, Hattori K, Hirota Y, Hoshino A, et al. Treatment of acute myelogenous leukemia in adults with N4-behenoyl-1-β-D-arabinofuranosylcytosine. Cancer 1985; 56: 1913–1917
   PubMed Web of Science ®Google Scholar
• Ohno R, Kato Y, Nagura E, Murase T, Okumura M, Yamada H, et al. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length. J Clin Oncol 1986; 4: 1740–1747
   PubMed Web of Science ®Google Scholar
• Yoshida M, Suda K, Tsuboyama A, Sasaki R, Kitagawa S, Kano Y, et al. Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults. Eur J Haematol 1989; 43: 1–6
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ueda T. Pharmacokinetics and action mechanism of N4-behenoyl-1-β-D-arabinofuranosylcytosine (BHAC) in leukemia chemotherapy. Cancer Chemotherapy: Challenges for the Future, K Kimura, K Yamada, E Frei, III, S K Carter. Excerpta Medica, Tokyo 1988; 3: 289–295
   Google Scholar
• Aoshima M, Tsukagoshi S, Sakurai Y, Oh-ishi J, Ishida T, Kobayashi H. N4-Behenoyl-1-β-D-arabinofuranosylcytosine as a potential new antitumor agent. Cancer Res 1977; 37: 2481–2486
   PubMed Web of Science ®Google Scholar
• Ueda T, Nakamura T, Ando S, Kagawa D, Sasada M, Uchino H, et al. Pharmacokinetics of N4-behenoyl-1-β-D-arabinofuranosylcytosine in patients with acute leukemia. Cancer Res 1983; 43: 3412–3416
   PubMed Web of Science ®Google Scholar
• Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 1989; 49: 3823–3828
   PubMed Web of Science ®Google Scholar
• Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, et al. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Int J Hematol 1999; 70: 97–104
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer Jan 24, 2006, [Epub ahead of print]
   Google Scholar
• Öberg G, Killander A, Björeman M, Gahrton G, Grimfors G, Gruber A, et al. Long-term follow-up of patients ≥ 60-year-old with acute myeloid leukaemia treated with intensive chemotherapy. Eur J Haematol 2002; 68: 376–381
   PubMed Web of Science ®Google Scholar
• Rowe J M, Neuberg D, Friedenberg W, Bennett J M, Paietta E, Makary A Z, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103: 479–485
   PubMed Web of Science ®Google Scholar
• Baer M R, George S L, Dodge R K, O'Loughlin K L, Minderman H, Caligiuri M A, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224–1232
   PubMed Web of Science ®Google Scholar
• Goldstone A H, Burnett A K, Wheatley K, Smith A G, Hutchinson R M, Clark R E. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1302–1311
   PubMed Web of Science ®Google Scholar
• Wahlin A, Markevärn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115: 25–33
   PubMed Web of Science ®Google Scholar
• Löfgren C, Paul C, Åström M, Hast R, Hedenius M, Lerner R, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial. Br J Haematol 2004; 124: 474–480
   PubMed Web of Science ®Google Scholar
• Gupta V, Chun K, Yi Q L, Minden M, Schuh A, Wells R, et al. Disease biology rather than age is the most important determinant of survival of patients ≥ 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 2005; 103: 2082–2090
   PubMed Web of Science ®Google Scholar
• Anderson J E, Kopecky K J, Willman C L, Head D, O'Donnell M R, Luthardt F W, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100: 3869–3876
   PubMed Web of Science ®Google Scholar
• Reiffers J, Raynal F, Broustet A. Acute myeloblastic leukemia in elderly patients: treatment and prognostic factors. Cancer 1980; 45: 2816–2820
   PubMed Web of Science ®Google Scholar